0001558370-22-017185.txt : 20221109 0001558370-22-017185.hdr.sgml : 20221109 20221109163707 ACCESSION NUMBER: 0001558370-22-017185 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHIBRO ANIMAL HEALTH CORP CENTRAL INDEX KEY: 0001069899 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 131840497 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36410 FILM NUMBER: 221373270 BUSINESS ADDRESS: STREET 1: GLENPOINTE CENTRE EAST, 3RD FLOOR STREET 2: 300 FRANK W. BURR BLVD., SUITE 21 CITY: TEANECK STATE: NJ ZIP: 07666 BUSINESS PHONE: 201-329-7300 MAIL ADDRESS: STREET 1: GLENPOINTE CENTRE EAST, 3RD FLOOR STREET 2: 300 FRANK W. BURR BLVD., SUITE 21 CITY: TEANECK STATE: NJ ZIP: 07666 FORMER COMPANY: FORMER CONFORMED NAME: PHILIPP BROTHERS CHEMICALS INC DATE OF NAME CHANGE: 19980908 8-K 1 pahc-20221109x8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 9, 2022

Phibro Animal Health Corporation

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)


Delaware	001-36410	13-1840497
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Glenpointe Centre East, 3rd Floor

300 Frank W. Burr Boulevard, Suite 21

Teaneck, New Jersey 07666-6712

(Address of Principal Executive Offices, including Zip Code)

(201) 329-7300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share		PAHC		NASDAQ Stock Market

Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On November 9, 2022, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended September 30, 2022 and its financial guidance for the fiscal year ending June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release, dated November 9, 2022.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PHIBRO ANIMAL HEALTH CORPORATION Registrant

Date: November 9, 2022

	By:	/s/ Thomas G. Dagger
	Name:	Thomas G. Dagger
	Title:	Senior Vice President, General Counsel and Corporate Secretary

EX-99.1 2 pahc-20221109xex99d1.htm EX-99.1

Exhibit 99.1

For Immediate Release

Phibro Animal Health Corporation Reports First Quarter Results, Revised Guidance

TEANECK, N.J., November 9, 2022 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2022, and reiterated its financial guidance for Net sales and Adjusted EBITDA and revised its guidance for Net income, Diluted EPS, Adjusted net income, Adjusted diluted EPS and Adjusted effective tax rate for the year ending June 30, 2023.

Highlights for the three months ended September 30, 2022 (compared to the three months ended September 30, 2021)

-Net sales of $232.5 million, an increase of $17.9 million, or 8%

-Net income of $3.9 million, a decrease of $2.7 million, or 41%

-Diluted EPS of $0.10, a decrease of $0.07, or 41%

-Adjusted EBITDA of $22.1 million, a decrease of $0.3 million, or 1%

-Adjusted net income of $8.3 million, a decrease of $1.9 million, or 18%

-Adjusted diluted EPS of $0.21, a decrease of $0.05, or 18%

COMMENTARY

“We continue to be encouraged by the Company’s sales performance as it reflects continued growth in the demand for our products, particularly in our largest regions, the United States and Latin America & Canada. Overall, our financial performance reflects typical seasonality trends and was in line with our internal expectations,” said Jack Bendheim, Phibro’s Chairman, President, and Chief Executive Officer.

Jack continued, “We were successful in resolving labor and logistic challenges with one of our critical suppliers, although it did have an unfavorable impact on the adjusted EBITDA contributed by our Animal Health segment this quarter. I am glad this is behind us, and we are looking forward to seeing further benefits this fiscal year from strategic investments we’ve made in our vaccine and nutritional specialty businesses as well as seeing our companion animal development pipeline continue to progress. We reiterate our full-year net sales guidance of $960 million to $1 billion, and $113 million to $118 million of adjusted EBITDA, but due to rising interest rates and changes in tax legislation, have revised our guidance for other key financial metrics.”

QUARTERLY RESULTS

Net sales

Net sales of $232.5 million for the three months ended September 30, 2022, increased $17.9 million, or 8%, as compared to the three months ended September 30, 2021. Animal Health and Mineral Nutrition increased $13.9 million and $5.2 million, respectively. Performance Products decreased $1.2 million.

Animal Health

Net sales of $154.9 million for the three months ended September 30, 2022, increased $13.9 million, or 10%. Net sales of MFAs and other increased $9.0 million, or 11%, primarily driven by increased sales of processing aids used in the ethanol fermentation industry. Net sales of nutritional specialty products increased $3.1 million, or 8%, due mostly to higher demand for dairy products. Net sales of vaccines increased $1.8 million, or 8%, due to increased domestic demand.

Mineral Nutrition

Net sales of $59.6 million for the three months ended September 30, 2022, increased $5.2 million, or 10%, primarily driven by higher average selling prices of trace minerals. The increase in average selling prices is correlated to the movement of the underlying raw material costs.

Performance Products

Net sales of $18.0 million for the three months ended September 30, 2022, decreased $1.2 million, or 6%, as a result of lower demand for copper-based products, partially offset by higher volumes of ingredients for personal care products and higher average selling prices of copper-based products.

Gross profit

Gross profit of $68.6 million for the three months ended September 30, 2022, increased $4.0 million, or 6%, as compared to the three months ended September 30, 2021. Gross margin decreased 60 basis points to 29.5% of net sales for the three months ended September 30, 2022, as compared to 30.1% for the three months ended September 30, 2021, due primarily to changes in product and geographical mix.

Animal Health gross profit increased $2.5 million, primarily driven by higher sales volume, offset by increased raw material and logistics costs. Mineral Nutrition gross profit increased $0.9 million, driven primarily by higher average selling prices, partially offset by an increase in raw material costs. Performance Products gross profit increased $0.5 million as a result of higher sales volumes of ingredients for personal care products, partially offset by increased raw material and production costs of copper-based products.

Selling, general and administrative expenses

Selling, general and administrative expenses (“SG&A”) of $55.0 million for the three months ended September 30, 2022, increased $4.9 million, or 10%, as compared to the three months ended September 30, 2021.

Animal Health SG&A increased $3.7 million, primarily due to an increase in the number of employees and employee-related costs. Mineral Nutrition and Performance Products SG&A increased $0.1 million and $0.3 million, respectively. Corporate costs increased by $0.8 million, driven by net changes in costs related to, but not limited to, employees, professional fees, technology and strategic investments.

Interest expense, net

Interest expense, net of $3.1 million for the three months ended September 30, 2022, increased by $0.2 million, as compared to the three months ended September 30, 2021, as a result of increased variable interest rates.

Foreign currency losses, net

Foreign currency losses, net for the three months ended September 30, 2022, were $5.2 million, as compared to $2.1 million of net losses for the three months ended September 30, 2021. Current period losses were mostly driven by the movement of the Brazilian and Argentine currencies relative to the U.S. dollar.

Provision for income taxes

The provision for income taxes was $1.6 million and $3.1 million for the three months ended September 30, 2022 and 2021, respectively. The effective income tax rate was 28.8% and 31.9% for the three months ended September 30, 2022 and 2021, respectively. The current provision for income taxes was impacted by the final foreign tax credit regulations that went into effect on July 1, 2022. The provision for income taxes during the three months ended September 30, 2022, included a $0.9 million benefit related to exchange rate differences on intercompany dividends and a $0.2 million expense from changes in uncertain tax positions related to prior years. The effective income tax rate, without these items, would have been 42.8% for the three months ended September 30, 2022. The provision for income taxes during the three months ended September 30, 2021, included a $0.4 million expense resulting from changes in uncertain tax positions related to prior years. The effective income tax rate, without this expense, would have been 27.4% for the three months ended September 30, 2021.

Net income

Net income of $3.9 million for the three months ended September 30, 2022, decreased $2.7 million, as compared to net income of $6.5 million for the three months ended September 30, 2021. Operating income decreased $0.9 million, driven by higher SG&A, partially offset by favorable gross profit. The increase in gross profit was due to higher product demand and higher selling prices. Interest expense, net increased slightly and foreign currency losses, net increased $3.1 million. Income tax expense decreased by $1.5 million.

Adjusted EBITDA

Adjusted EBITDA of $22.1 million for the three months ended September 30, 2022, decreased $0.3 million, as compared to the three months ended September 30, 2021. Animal Health Adjusted EBITDA decreased $0.7 million due to higher SG&A, partially offset by higher revenue and gross profit. Mineral Nutrition Adjusted EBITDA increased $0.8 million, driven by increased gross profit. Performance Products Adjusted EBITDA increased $0.2 million due to a favorable sales mix, partially offset by increased SG&A. Corporate expenses increased $0.6 million, driven by net changes in costs related to, but not limited to, employees, professional fees, technology and strategic investments.

Adjusted provision for income taxes

The adjusted effective income tax rates for the three months ended September 30, 2022 and 2021, were 36.0% and 26.4%, respectively. The increase in our adjusted effective income tax rate was driven by changes in the final foreign tax credit regulations that went into effect on July 1, 2022.

Adjusted Net Income

Adjusted net income of $8.3 million for the three months ended September 30, 2022, decreased $1.9 million, or 18%, as compared to the prior year. The decrease was driven by higher SG&A and a higher tax provision, offset by higher gross profit. The increase in gross profit resulted from higher sales, partially offset by higher raw material and production costs. SG&A expenses increased due to net changes in costs related to, but not limited to, employees, professional fees, technology and strategic investments.

Adjusted diluted EPS

Adjusted diluted EPS was $0.21 for the quarter, a decrease of $0.05, or 18%, as compared to $0.25 in the prior year.

BALANCE SHEET AND CASH FLOWS

●

Free cash flow was $(20.6) million⁽¹⁾ for the twelve months ended September 30, 2022

●

4.2x gross leverage ratio as of September 30, 2022

-$468 million total debt

-$111 million Adjusted EBITDA for the twelve months ended September 30, 2022

●

Liquidity of $163 million, consisting of $86 million of cash and short-term investments on hand and $77 million of available revolving credit (subject to leverage ratio limitations) as of September 30, 2022. Subsequently to quarter-end, we increased the available revolving credit by $60 million, to a maximum of $310 million (subject to leverage ratio limitations).

(1)

Free cash flow equals cash flow from operating activities less capital expenditures for the trailing 12-months ended September 30, 2022, excluding a $15 million purchase of property financed in part by a secured term loan during the quarter ended September 30, 2022, included within capital expenditures in the Consolidated Statements of Cash Flows, included in Item 1 of our most recent Quarterly Report on Form 10-Q. In the first quarter, we had a significant and planned inventory build which is typical and driven primarily by our Mineral Nutrition business based in Quincy, Illinois, where an adequate level of inventory is needed to minimize logistical issues presented when the Mississippi River freezes.

The Company’s goal is to end our fiscal year with less debt and improved gross and net leverage ratios in comparison to what we reported at the end of our first quarter.

FISCAL YEAR 2023 FINANCIAL GUIDANCE

The Company reiterated its guidance for Net sales and Adjusted EBITDA and revised its guidance for Net income, Diluted EPS, Adjusted net income, Adjusted diluted EPS and Adjusted effective tax rate.

The updates reflect increased interest expense, net, due to higher interest rates and debt outstanding, and the projected impact of recently released final tax regulations that eliminate U.S. creditability of the Brazil income tax beginning with our current fiscal year. Guidance for GAAP measures assumes actual foreign exchange losses for the quarter ended September 30, 2022, and the Company’s projected foreign exchanges rates for the nine months ending June 30, 2023.

Financial guidance for the year ending June 30, 2023, is as follows:

●

Net sales of $960 million - $1 billion (unchanged)

●

Net income of $39 - $43 million, from $45 - $49 million

●

Diluted EPS of $0.96 - $1.06, from $1.11 - $1.21

●

Adjusted EBITDA of $113 - $118 million (unchanged)

●

Adjusted net income of $49 - $53 million, from $52 - $56 million

●

Adjusted diluted EPS of $1.21 - $1.31, from $1.28 - $1.38

●

Adjusted effective tax rate of 33%, from 30%

WEBCAST & CONFERENCE CALL DETAILS

Phibro Animal Health Corporation will host a webcast and conference call during which the Company will review its financial results and respond to questions.

Date:

Thursday, November 10, 2022

Time:

9:00 AM Eastern

Location:

https://investors.pahc.com

U.S. Toll-Free:

+1 (888) 330-2022

International Toll:

+1 (365) 977-0051

Conference ID:

3927884

NOTE: To join this conference call, all participants will be required to provide the Conference ID number.

A replay of the webcast will be archived and made available on Phibro’s website.

DISCLOSURE NOTICES

Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.

Non-GAAP Financial Information: We use non-GAAP financial measures, such as adjusted EBITDA, adjusted net income, adjusted diluted EPS and free cash flow to assess and analyze our operational results and trends and to make financial and operational decisions. Management uses adjusted EBITDA as its primary operating measure. We report adjusted net income to portray the results of our operations prior to considering certain income statement elements. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this communication should not be considered alternatives to measurements required by GAAP, such as net income, operating income and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this communication and/or our Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

We are not providing a reconciliation of forward-looking guidance of non-GAAP financial measures to the most directly comparable GAAP financial measures because of the uncertainty regarding, and the potential variability of, certain of the items required for a reconciliation; accordingly, a reconciliation of the non-GAAP financial measure to the corresponding GAAP financial measure is not available without unreasonable effort.

Internet Posting of Information: We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Phibro Animal Health Corporation

Consolidated Results of Operations


	Three Months
For the Periods Ended September 30	2022			2021			Change

	(in millions, except per share amounts and percentages)
Net sales	$	232.5		$	214.7		$	17.9	8	%
Cost of goods sold		163.9			150.0			13.9	9	%
Gross profit		68.6			64.7			4.0	6	%
Selling, general and administrative		55.0			50.1			4.9	10	%
Operating income		13.7			14.6			(0.9)	(6)	%
Interest expense, net		3.1			2.9			0.2	6	%
Foreign currency losses, net		5.2			2.1			3.1	*
Income before income taxes		5.4			9.6			(4.2)	(44)	%
Provision for income taxes		1.6			3.1			(1.5)	*
Net income	$	3.9		$	6.5		$	(2.7)	(41)	%

Net income per share - basic and diluted	$	0.10		$	0.16		$	(0.07)	(41)	%

Weighted average common shares outstanding
basic and diluted		40.5			40.5

Ratio to net sales
Gross profit		29.5	%		30.1	%
Selling, general and administrative		23.6	%		23.3	%
Operating income		5.9	%		6.8	%
Income before income taxes		2.3	%		4.5	%
Net income		1.7	%		3.0	%
Effective tax rate		28.8	%		31.9	%

Amounts and percentages may reflect rounding adjustments

*Calculation not meaningful

Phibro Animal Health Corporation

Segment Net Sales and Adjusted EBITDA


	Three Months
For the Periods Ended September 30	2022			2021			Change

	(in millions, except percentages)
Net Sales
MFAs and other	$	92.8		$	83.8		$	9.0	11	%
Nutritional specialties		39.1			36.0			3.1	8	%
Vaccines		23.0			21.2			1.8	8	%
Animal Health		154.9			141.0			13.9	10	%
Mineral Nutrition		59.6			54.4			5.2	10	%
Performance Products		18.0			19.2			(1.2)	(6)	%
Total	$	232.5		$	214.7		$	17.9	8	%

Adjusted EBITDA
Animal Health	$	27.0		$	27.6		$	(0.7)	(2)	%
Mineral Nutrition		5.3			4.5			0.8	17	%
Performance Products		2.4			2.1			0.2	11	%
Corporate		(12.5)			(11.8)			(0.6)	5	%
Total	$	22.1		$	22.5		$	(0.3)	(1)	%

Ratio to segment net sales
Animal Health		17.4	%		19.6	%
Mineral Nutrition		8.9	%		8.3	%
Performance Products		13.1	%		11.1	%
Corporate ⁽¹⁾		(5.4)	%		(5.5)	%
Total ⁽¹⁾		9.5	%		10.5	%
⁽¹⁾reflects ratio to total net sales

Reconciliation of GAAP Net Income to Adjusted EBITDA
Net income	$	3.9		$	6.5		$	(2.7)	(41)	%
Interest expense, net		3.1			2.9			0.2	6	%
Provision for income taxes		1.6			3.1			(1.5)	(49)	%
Depreciation and amortization		8.5			7.9			0.6	8	%
EBITDA		16.9			20.3			(3.4)	(17)	%
Foreign currency losses, net		5.2			2.1			3.1	*
Adjusted EBITDA	$	22.1		$	22.5		$	(0.3)	(1)	%

Amounts and percentages may reflect rounding adjustments

* Calculation not meaningful

Phibro Animal Health Corporation

Adjusted Net Income


	Three Months
For the Periods Ended September 30	2022			2021			Change

	(in millions, except per share amounts and percentages)
Reconciliation of GAAP Net Income to Adjusted Net Income
Net income	$	3.9		$	6.5		$	(2.7)	(41)	%
Acquisition-related intangible amortization⁽¹⁾		1.7			1.5			0.2	12	%
Acquisition-related intangible amortization⁽²⁾		0.7			0.7			0.1	13	%
Foreign currency losses, net⁽³⁾		5.2			2.1			3.1	*
Adjustments to income taxes⁽⁴⁾		(3.1)			(0.6)			(2.5)	*
Adjusted net income	$	8.3		$	10.2		$	(1.9)	(18)	%

Statement of Operations Line Items - adjusted
Adjusted cost of goods sold⁽¹⁾	$	162.2		$	148.5		$	13.7	9	%
Adjusted gross profit		70.3			66.2			4.1	6	%
Adjusted selling, general and administrative⁽²⁾		54.2			49.4			4.8	10	%
Adjusted interest expense, net		3.1			2.9			0.2	6	%
Adjusted income before income taxes		13.0			13.9			(0.8)	(6)	%
Adjusted provision for income taxes⁽⁴⁾		4.7			3.7			1.0	28	%
Adjusted net income	$	8.3		$	10.2		$	(1.9)	(18)	%

Adjusted net income per share
diluted	$	0.21		$	0.25		$	(0.05)	(18)	%

Weighted average common shares outstanding
diluted		40.5			40.5

Ratio to net sales
Adjusted gross profit		30.2	%		30.8	%
Adjusted selling, general and administrative		23.3	%		23.0	%
Adjusted income before income taxes		5.6	%		6.5	%
Adjusted net income		3.6	%		4.8	%
Adjusted effective tax rate		36.0	%		26.4	%

Amounts and percentages may reflect rounding adjustments

*	Calculation not meaningful

⁽¹⁾	Adjusted cost of goods sold excludes acquisition-related intangible amortization

⁽²⁾	Adjusted selling, general and administrative excludes acquisition-related intangible amortization

⁽³⁾	Foreign currency losses, net are excluded from adjusted net income

⁽⁴⁾	Adjusted provision for income taxes excludes the income tax effect of pre-tax income adjustments and certain income tax items

Phibro Animal Health Corporation

Operating and Investing Cash Flows


	Three Months
For the Periods Ended September 30	2022		2021		Change

	(in millions)
EBITDA	$	16.9	$	20.3	$	(3.4)
Adjustments
Foreign currency losses, net		5.2		2.1		3.1
Interest paid, net		(2.9)		(2.7)		(0.2)
Income taxes paid		(3.8)		(3.0)		(0.8)
Changes in operating assets and liabilities and other items		(26.1)		(13.0)		(13.2)
Net cash (used in) provided by operating activities	$	(10.7)	$	3.8	$	(14.5)

Short-term investments, net	$	7.0	$	(13.0)	$	20.0
Capital expenditures		(23.2)		(7.4)		(15.7)
Other investing, net		0.0		(0.2)		0.2
Net cash used by investing activities	$	(16.1)	$	(20.7)	$	4.5
Net cash flow before financing activities	$	(26.8)	$	(16.8)	$	(10.0)

Amounts and percentages may reflect rounding adjustments

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.

Contacts

Phibro Animal Health Corporation

Damian Finio

Chief Financial Officer

+1-201-329-7300

investor.relations@pahc.com

GRAPHIC 3 pahc-20221109xex99d1001.jpg GRAPHIC begin 644 pahc-20221109xex99d1001.jpg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end EX-101.SCH 4 pahc-20221109.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pahc-20221109_lab.xml EX-101.LAB Cover [Abstract] Document Type Document Period End Date Entity Registrant Name Entity Incorporation, State or Country Code Entity File Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Adress Line Two Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Central Index Key Amendment Flag EX-101.PRE 6 pahc-20221109_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Nov. 09, 2022
Cover [Abstract]
Document Type	8-K
Document Period End Date	Nov. 09, 2022
Entity Registrant Name	Phibro Animal Health Corporation
Entity Incorporation, State or Country Code	DE
Entity File Number	001-36410
Entity Tax Identification Number	13-1840497
Entity Address, Address Line One	Glenpointe Centre East, 3rd Floor
Entity Address, Adress Line Two	300 Frank W. Burr Boulevard, Suite 21
Entity Address, City or Town	Teaneck
Entity Address State Or Province	NJ
Entity Address, Postal Zip Code	07666-6712
City Area Code	201
Local Phone Number	329-7300
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Trading Symbol	PAHC
Security Exchange Name	NASDAQ
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0001069899
Amendment Flag	false

XML 8 pahc-20221109x8k_htm.xml IDEA: XBRL DOCUMENT 0001069899 2022-11-09 2022-11-09 0001069899 false 8-K 2022-11-09 Phibro Animal Health Corporation DE 001-36410 13-1840497 Glenpointe Centre East, 3rd Floor 300 Frank W. Burr Boulevard, Suite 21 Teaneck NJ 07666-6712 201 329-7300 Class A Common Stock, $0.0001 par value per share PAHC NASDAQ false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.pahc.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports pahc-20221109x8k.htm pahc-20221109.xsd pahc-20221109_lab.xml pahc-20221109_pre.xml pahc-20221109xex99d1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pahc-20221109x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "pahc-20221109x8k.htm" ] }, "labelLink": { "local": [ "pahc-20221109_lab.xml" ] }, "presentationLink": { "local": [ "pahc-20221109_pre.xml" ] }, "schema": { "local": [ "pahc-20221109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pahc", "nsuri": "http://www.pahc.com/20221109", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "pahc-20221109x8k.htm", "contextRef": "Duration_11_9_2022_To_11_9_2022_C_I9SOMZz0WX1SnFL61epA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.pahc.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "pahc-20221109x8k.htm", "contextRef": "Duration_11_9_2022_To_11_9_2022_C_I9SOMZz0WX1SnFL61epA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.pahc.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001558370-22-017185-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-017185-xbrl.zip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end